An Overview of COVID-19: Focus on Pharmacological Aspect

Coronavirus disease 2019 (COVID-19) which has been declared as Public Health Emergency of International Concern by the World Health Organization (WHO) is one of the major disasters in the 21st century. Initially, COVID-19 is called as 2019 novel coronavirus by the Chinese researchers, and later, the disease was named as COVID-19 and the virus as SARS-CoV-2 by the International Committee on Taxonomy of Viruses. It is a single-stranded RNA virus that mainly enters the human cells by angiotensin-converting enzyme 2 (ACE2) receptors like SARS-CoV. The important mode of transmission is through droplets and close contact with the infected people. As soon as the virus enters the human cells, it causes symptoms like cough, fever, headache, and fatigue after an incubation period of 5.2 days. There is no approved treatment or vaccine for this disease so far but many drugs have been tried from the experience obtained while treating SARS-CoV and MERS-CoV. In this article, we discussed the pathogenesis, transmission, clinical features, challenges for control, diagnosis, and treatment advancements to overcome COVID-19.

[1]  N. Bashir,et al.  COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses , 2020, Journal of Advanced Research.

[2]  W. Ko,et al.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges , 2020, International Journal of Antimicrobial Agents.

[3]  Jindrich Cinatl,et al.  HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.

[4]  P. Barnes,et al.  Nitric oxide and airway disease. , 1995, Annals of medicine.

[5]  Zhenghong Yuan,et al.  Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. , 2009, The Journal of general virology.

[6]  Lisa E. Gralinski,et al.  Return of the Coronavirus: 2019-nCoV , 2020, Viruses.

[7]  A. Jadad,et al.  No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19 , 2020, JMIRx med.

[8]  L. Saif Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome? , 2004, Revue scientifique et technique.

[9]  R. Baric,et al.  Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture , 2010, PLoS pathogens.

[10]  A. Al-Osail,et al.  The history and epidemiology of Middle East respiratory syndrome corona virus , 2017, Multidisciplinary Respiratory Medicine.

[11]  Xiaotao Lu,et al.  Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.

[12]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[13]  S. Perlman,et al.  ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia , 2005, Journal of Virology.

[14]  B. Willms,et al.  Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. , 1980, Hormone and metabolic research. Supplement series.

[15]  Shibo Jiang,et al.  Recent advances in the detection of respiratory virus infection in humans , 2020, Journal of medical virology.

[16]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[17]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[18]  Weier Wang,et al.  Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China , 2020, Journal of medical virology.

[19]  C. Midgley,et al.  Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia , 2019, Emerging infectious diseases.

[20]  B. Fielding,et al.  Coronavirus envelope protein: current knowledge , 2019, Virology Journal.

[21]  S. Sawicki,et al.  Coronavirus Transcription: A Perspective , 2005, Current topics in microbiology and immunology.

[22]  R. Hilgenfeld From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design , 2014, The FEBS journal.

[23]  Jindrich Cinatl,et al.  Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines , 2004, Biochemical and Biophysical Research Communications.

[24]  Z. Cao,et al.  Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses , 2011, Peptides.

[25]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[26]  Catharine I Paules,et al.  Coronavirus Infections-More Than Just the Common Cold. , 2020, JAMA.

[27]  V. Misra,et al.  Bats and Coronaviruses , 2019, Viruses.

[28]  Jie Dong,et al.  Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study , 2020, Chinese medical journal.

[29]  Malik Peiris,et al.  Middle East respiratory syndrome , 2015, The Lancet.

[30]  E. Collisson,et al.  Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[31]  Qianyun Liu,et al.  Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.

[32]  M. Kikkert,et al.  Host Factors in Coronavirus Replication , 2017, Current topics in microbiology and immunology.

[33]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[34]  I Rovira,et al.  Nitric oxide , 2021, Reactions Weekly.

[35]  Xiaolong Qi,et al.  CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia , 2020, Radiology.

[36]  D. Veesler,et al.  Structural insights into coronavirus entry , 2019, Advances in Virus Research.

[37]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[38]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[39]  J. Bussel,et al.  Uses of intravenous gammaglobulin in immune hematologic disease. , 1995, Immunological investigations.

[40]  Yan Zhao,et al.  A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) , 2020, Military Medical Research.

[41]  H. Ho,et al.  Glucose-6-Phosphate Dehydrogenase Deficiency Enhances Human Coronavirus 229E Infection , 2008, The Journal of infectious diseases.

[42]  David Shum,et al.  Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.

[43]  V. A. Maksimov,et al.  [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. , 2008, Voprosy virusologii.

[44]  H. Rothan,et al.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.

[45]  Yunhui Liu,et al.  Potential interventions for novel coronavirus in China: A systematic review , 2020, Journal of medical virology.

[46]  P. Hawkey,et al.  Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. , 2003, Journal of medical microbiology.

[47]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[48]  E. Won,et al.  Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome , 2015, Antiviral therapy.

[49]  G. Kroemer,et al.  Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses , 2020, Cell stress.

[50]  C. Meschievitz,et al.  Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon , 1986, The Journal of infectious diseases.

[51]  D. Wang,et al.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.

[52]  B. Medhi,et al.  Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach , 2020, Indian journal of pharmacology.

[53]  M. Dayer,et al.  Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study , 2017 .

[54]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[55]  S. Hewitt,et al.  Neuraminidase inhibitors for treatment of influenza A and B infections. , 1999, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[56]  D. Tai Pharmacologic treatment of SARS: current knowledge and recommendations. , 2007, Annals of the Academy of Medicine, Singapore.

[57]  R. Rossaint,et al.  Efficacy of inhaled nitric oxide in patients with severe ARDS. , 1995, Chest.

[58]  Andrea Marzi,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[59]  B. Medhi,et al.  Drug targets for corona virus: A systematic review , 2020, Indian journal of pharmacology.

[60]  Z. Rao,et al.  Drug design targeting the main protease, the Achilles' heel of coronaviruses. , 2006, Current pharmaceutical design.

[61]  A. Phelan,et al.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.

[62]  Z. Memish,et al.  Reducing mortality from 2019-nCoV: host-directed therapies should be an option , 2020, The Lancet.

[63]  Chung-ke Chang,et al.  Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein , 2015, Drug Discovery Today.

[64]  Ralph S. Baric,et al.  Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission , 2009, Journal of Virology.

[65]  G. Whittaker,et al.  Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein , 2012, Viruses.

[66]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.